6.
Dent P
. FADD the bad in head and neck cancer. Cancer Biol Ther. 2013; 14(9):780-1.
PMC: 3909546.
DOI: 10.4161/cbt.26151.
View
7.
Fang L, Wu S, Zhu X, Cai J, Wu J, He Z
. MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-β pathway in NSCLC. Oncogene. 2018; 38(6):896-912.
PMC: 6756124.
DOI: 10.1038/s41388-018-0484-9.
View
8.
Freier K, Sticht C, Hofele C, Flechtenmacher C, Stange D, Puccio L
. Recurrent coamplification of cytoskeleton-associated genes EMS1 and SHANK2 with CCND1 in oral squamous cell carcinoma. Genes Chromosomes Cancer. 2005; 45(2):118-25.
DOI: 10.1002/gcc.20270.
View
9.
Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S
. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1.
PMC: 4160307.
DOI: 10.1126/scisignal.2004088.
View
10.
Glinsky G
. Integration of HapMap-based SNP pattern analysis and gene expression profiling reveals common SNP profiles for cancer therapy outcome predictor genes. Cell Cycle. 2006; 5(22):2613-25.
DOI: 10.4161/cc.5.22.3498.
View
11.
Goldman M, Craft B, Hastie M, Repecka K, McDade F, Kamath A
. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38(6):675-678.
PMC: 7386072.
DOI: 10.1038/s41587-020-0546-8.
View
12.
Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain J
. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004; 22(13):2594-601.
DOI: 10.1200/JCO.2004.08.067.
View
13.
Heist R, Zhou W, Chirieac L, Cogan-Drew T, Liu G, Su L
. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol. 2007; 25(16):2243-7.
DOI: 10.1200/JCO.2006.08.8914.
View
14.
Izzo J, Wu T, Wu X, Ensor J, Luthra R, Pan J
. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol. 2007; 25(6):698-707.
DOI: 10.1200/JCO.2006.08.0283.
View
15.
Jamroziak K, Robak T
. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology. 2004; 9(2):91-105.
DOI: 10.1080/10245330310001638974.
View
16.
Janssen J, Vaandrager J, Heuser T, Jauch A, Kluin P, Geelen E
. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood. 2001; 95(8):2691-8.
View
17.
Janssen J, Cuny M, Orsetti B, Rodriguez C, Valles H, Bartram C
. MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer. Int J Cancer. 2002; 102(6):608-14.
DOI: 10.1002/ijc.10765.
View
18.
Janssen J, Imoto I, Inoue J, Shimada Y, Ueda M, Imamura M
. MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas. J Hum Genet. 2002; 47(9):460-4.
DOI: 10.1007/s100380200065.
View
19.
Li Y, Zhang J, Hong S
. ANO1 as a marker of oral squamous cell carcinoma and silencing ANO1 suppresses migration of human SCC-25 cells. Med Oral Patol Oral Cir Bucal. 2013; 19(4):e313-9.
PMC: 4119304.
DOI: 10.4317/medoral.19076.
View
20.
Liang E, Lu Y, Shi Y, Zhou Q, Zhi F
. MYEOV increases HES1 expression and promotes pancreatic cancer progression by enhancing SOX9 transactivity. Oncogene. 2020; 39(41):6437-6450.
DOI: 10.1038/s41388-020-01443-4.
View